Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02673333 · ClinicalTrials.gov registry record · Phase 2
Single Agent Pembrolizumab in Subjects With Advanced Adrenocortical Carcinoma
A Phase 2 study of Adrenocortical Carcinoma, sponsored by Memorial Sloan Kettering Cancer Center.
- Active
- Registry status
- Phase 2
- Development phase
- 39
- Enrollment target
- 2
- Study locations
NCT02673333: Active Phase 2 study of Adrenocortical Carcinoma, sponsored by Memorial Sloan Kettering Cancer Center.
NCT02673333 is a Phase 2 study of Adrenocortical Carcinoma that is active but no longer recruiting, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 39 participants, below the 359-participant average among 8 other Adrenocortical Carcinoma trials with a reported enrollment target (89% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02673333, a Phase 2 study of Adrenocortical Carcinoma, is active but no longer recruiting, sponsored by Memorial Sloan Kettering Cancer Center.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 39 participants
- Enrollment target
- 2
- Study locations
Study Summary
Pembrolizumab is a type of immunotherapy, and the purpose of this study is to find out what effects, good and/or bad, pembrolizumab has on you, and your cancer.
Primary Outcome
using RECIST v1.1 A Simon two stage minimax design will be employed to carry out this objective. In the first stage, 21 patients will be enrolled. If at least 3 out of 21 patients respond (partial response - PR or complete response - CR), we will enroll an additional 18 patients for a total of 39 patients. At the end of the study, 8 of 39 patients will need to respond to consider the therapy promising. The study will be complete when all subjects have either completed 24 months of drug therapy,
Conditions Studied
Interventions
- DRUG Pembrolizumab
Study Locations (2)
Michigan
- University of Michigan (Data or Specimen Analysis Only) - Ann Arbor
New York
- Memorial Sloan Kettering Cancer Center - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 39 participants |
| Start Date | 2016-02 |
| Est. Completion | 2026-02 |
| Phase | Phase 2 |
What the registry record for NCT02673333 still lists
NCT02673333 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 39 participants, a relatively small participant target, below the 359-participant average among 8 other Adrenocortical Carcinoma trials with a reported enrollment target (89% lower).
The record links to 1 condition, with Adrenocortical Carcinoma appearing as the primary indexed condition, and to 1 intervention - of which Pembrolizumab is the first listed.
NCT02673333 reports a single indexed study location in Michigan, New York.
Frequently Asked Questions
What is clinical trial NCT02673333 about?
NCT02673333 is a clinical study titled "Single Agent Pembrolizumab in Subjects With Advanced Adrenocortical Carcinoma". Pembrolizumab is a type of immunotherapy, and the purpose of this study is to find out what effects, good and/or bad, pembrolizumab has on you, and your cancer.
What is the current status of trial NCT02673333?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 39 participants. The study started on 2016-02. Estimated completion is 2026-02.
What conditions does trial NCT02673333 study?
This clinical trial studies the following conditions: Adrenocortical Carcinoma.
What interventions are being tested in trial NCT02673333?
The interventions under investigation include: Pembrolizumab (DRUG).
Who is sponsoring clinical trial NCT02673333?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02673333 being conducted?
This trial has 2 study locations across Michigan, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Adrenocortical Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02673333's enrollment target sits among peer trials
39 7th of 8 higher than 2 of 8 other Adrenocortical Carcinoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Adrenocortical Carcinoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Study of Radiotherapy and Pembrolizumab in People With Adrenocortical Carcinoma
RECRUITING · Phase 2
-
Surgery and Heated Intraperitoneal Chemotherapy for Adrenocortical Carcinoma
RECRUITING · Phase 2
-
Nivolumab Combined With Ipilimumab for Patients With Advanced Rare Genitourinary Tumors
ACTIVE NOT RECRUITING · Phase 2
-
Familial Investigations of Childhood Cancer Predisposition
RECRUITING
-
Optimal Methods of Disease Progression and Survival Analysis in Children and Adults Patients With Adrenocortical Cancer (ACC)
ACTIVE NOT RECRUITING
-
Natural History Study of Infants With Adrenal Masses Found on Prenatal and/or Neonatal Imaging
COMPLETED
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03465592 · 39 participants · Phase 1
Trial of Nivolumab Following Partially Human Leukocyte Antigen (HLA) Mismatched BMT in Children & Adults With Sarcoma
- NCT03961776 · 39 participants
Monitoring Treatment Response With On-board DWI During Neo-adjuvant Chemo-radiation for Rectal Cancer Using Magnetic Resonance-guided-radiotherapy Systems
- NCT04050280 · 39 participants · Phase 2
CLAG-GO for Patients With Persistent, Relapsed or Refractory AML
- NCT04190862 · 39 participants · Phase 1
E-CEL UVEC as an Adjunct Cell Therapy for Treatment of Anal Fistulas
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia